Robinhood’s no-deal deals have attracted many investors. Millions of them are millennia jumping to invest for the first time.
With the onset of the COVID-19 pandemic, you can expect Robinhood investors to consider ways to take advantage of the coronavirus outbreak. And you will be right.
At least nine stocks of companies with coronavirus programs rank in the top 100 of the most popular stocks on the trading platform Robinhood. Here are the three most popular stocks of coronavirus – and whether they are smart photos to buy right now.
modern (NASDAQ: mRNA) ranks as the most popular stock of coronavirus of all in Robinhood. This is not surprising given the amount of attention that biotech stocks have received in recent months.
In January, Moderna announced that it was making rapid progress in developing a vaccine for RNA vaccine to prevent infection with the new coronavirus. By mid-March, the National Institution of Health was evaluating Moderna’s mVNA-1273 COVID-19 vaccine candidate in a phase 1 clinical trial.
Today, Moderna is one of the leaders in the race to develop a coronavirus vaccine. He launched a study at a late stage on July 27, which should enroll about 30,000 participants. Modern hopes to be able to seek FDA approval or emergency use approval by the end of this year.
Inovio Pharmaceuticals (NASDAQ: INO) takes the award as №2 most popular coronavirus action for investors in Robinhood. Biotechnology was better known for its late-stage candidate for cervical dysplasia, VGX-3100, coming in 2020. But, like Modern, Inovio moved quickly earlier this year to launch the COVID-19 vaccine program.
Until recently, no other drug manufacturer claimed a candidate for a phase 2 vaccine targeting any member of the coronavirus family other than Inovio. Inovio’s research on INO-4700, a candidate for a vaccine against coronavirus immunization that causes respiratory syndrome in the Middle East (MERS), gave the company a great starting point for its work on a vaccine candidate targeting a new coronavirus SARS-CoV-2. .
Inovio announced encouraging intermediate results from a phase 1 clinical trial of its COVID-19 vaccine candidate, INO-4800, on 30 June. The young biotechnologist hopes to move the INO-4800 to a phase study 2/3 later this summer.
Pfizer (NYSE: PFE) is the highest-ranked major pharmacy with a candidate for the COVID-19 vaccine under development in Robinhood’s list of the 100 most popular stocks. However, the big drugmaker comes a few places behind Inovio to take third place in coronavirus stocks on the trading platform.
In March, Pfizer announced that it was partnering with German biotechnology BioNTech 09.30 NASDAQ: BNTX to develop a candidate for the COVID-19 vaccine. The two companies have previously partnered to develop a flu vaccine for RNA.
Pfizer and BioNTech announced positive results from a phase 1/2 study of the BNT162 program in the United States and Germany in July. The companies selected a candidate, BNT162b2, to pass the main phase 2/3 testing. They also won a major deal with the US government to supply 100 million doses of the $ 1.95 billion vaccine, plus a deal with Japan to supply 100 million doses for an undisclosed amount.
Do they buy?
Inovio is probably the most risky choice among these popular Robinhood coronavirus stocks. Biotechnology has not yet provided all the details of its first study of the INO-4800. My opinion is that Inovio is definitely a stock to keep on your radar, but not one to buy yet.
Modern is also risky, especially given the high growth expectations already included in its share price. However, I think the chances of winning approval are pretty good now that the mRNA-1273 is in phase 3 testing. Modern could realistically achieve $ 15 billion or more in annual sales if the vaccine candidate is successful.
The rest of the experimental mRNA therapies and vaccines may also be considered more valuable if mRNA-1273 wins approval. I think Modern is a purchase, but only for aggressive investors who want to take a significant risk.
What about Pfizer? This is the least risky of Robinhood’s three most popular coronavirus stocks. Pfizer has many drivers for growth, even if BNT162b2 flops, including blood thinner Eliquis and rare disease drug Vyndaquel. However, I expect that BNT162b2 will succeed in testing at a late stage and will be another blockbuster for the big drug manufacturer.
Don’t worry, Pfizer’s growth has been anemic in recent years. The company’s Upjohn department detained him. But by merging Upjohn with Mylan on the road later this year, this shouldn’t be a problem for much longer. I guess conservative investors should consider buying Pfizer.